Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C. Lee MY, et al. Among authors: abdul sater h. J Immunother Cancer. 2021 Mar;9(3):e002128. doi: 10.1136/jitc-2020-002128. J Immunother Cancer. 2021. PMID: 33741731 Free PMC article.
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Robbins Y, Greene S, Friedman J, Clavijo PE, Van Waes C, Fabian KP, Padget MR, Abdul Sater H, Lee JH, Soon-Shiong P, Gulley J, Schlom J, Hodge JW, Allen CT. Robbins Y, et al. Among authors: abdul sater h. Elife. 2020 Jul 7;9:e54854. doi: 10.7554/eLife.54854. Elife. 2020. PMID: 32633234 Free PMC article.
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
Robbins Y, Friedman J, Clavijo PE, Sievers C, Bai K, Donahue RN, Schlom J, Sinkoe A, Hinrichs CS, Allen C, Abdul Sater H, Gulley JL, Norberg S. Robbins Y, et al. Among authors: abdul sater h. J Immunother Cancer. 2021 Aug;9(8):e003113. doi: 10.1136/jitc-2021-003113. J Immunother Cancer. 2021. PMID: 34462327 Free PMC article. Clinical Trial.
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M, McMahon S, Madan RA, Karzai F, Tsai YT, Donahue RN, Palena C, Jochems C, Marté JL, Floudas C, Strauss J, Redman J, Abdul Sater H, Rabizadeh S, Soon-Shiong P, Schlom J, Gulley JL. Bilusic M, et al. Among authors: abdul sater h. J Immunother Cancer. 2021 Mar;9(3):e002374. doi: 10.1136/jitc-2021-002374. J Immunother Cancer. 2021. PMID: 33762322 Free PMC article. Clinical Trial.
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
Abdul Sater H, Marté JL, Donahue RN, Walter-Rodriguez B, Heery CR, Steinberg SM, Cordes LM, Chun G, Karzai F, Bilusic M, Harmon SA, Turkbey IB, Choyke PL, Schlom J, Dahut WL, Madan RA, Pinto PA, Gulley JL. Abdul Sater H, et al. J Immunother Cancer. 2020 Mar;8(1):e000655. doi: 10.1136/jitc-2020-000655. J Immunother Cancer. 2020. PMID: 32269146 Free PMC article. Clinical Trial.
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.
Redman JM, Tsai YT, Weinberg BA, Donahue RN, Gandhy S, Gatti-Mays ME, Abdul Sater H, Bilusic M, Cordes LM, Steinberg SM, Marte JL, Jochems C, Kim SS, Marshall JL, McMahon S, Redmond E, Schlom J, Gulley JL, Strauss J. Redman JM, et al. Among authors: abdul sater h. Oncologist. 2022 Mar 11;27(3):198-209. doi: 10.1093/oncolo/oyab046. Oncologist. 2022. PMID: 35274710 Free PMC article. Clinical Trial.
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Collins JM, Donahue RN, Tsai YT, Manu M, Palena C, Gatti-Mays ME, Marté JL, Madan RA, Karzai F, Heery CR, Strauss J, Abdul-Sater H, Cordes L, Schlom J, Gulley JL, Bilusic M. Collins JM, et al. Among authors: abdul sater h. Oncologist. 2020 Jul;25(7):560-e1006. doi: 10.1634/theoncologist.2019-0932. Epub 2019 Dec 26. Oncologist. 2020. PMID: 31876334 Free PMC article. Clinical Trial.
If we build it they will come: targeting the immune response to breast cancer.
Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, Abdul Sater H, Sparano JA, Cescon D, Page DB, McArthur H, Adams S, Mittendorf EA. Gatti-Mays ME, et al. Among authors: abdul sater h. NPJ Breast Cancer. 2019 Oct 29;5:37. doi: 10.1038/s41523-019-0133-7. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31700993 Free PMC article. Review.
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.
Wilkinson S, Ye H, Karzai F, Harmon SA, Terrigino NT, VanderWeele DJ, Bright JR, Atway R, Trostel SY, Carrabba NV, Whitlock NC, Walker SM, Lis RT, Abdul Sater H, Capaldo BJ, Madan RA, Gulley JL, Chun G, Merino MJ, Pinto PA, Salles DC, Kaur HB, Lotan TL, Venzon DJ, Choyke PL, Turkbey B, Dahut WL, Sowalsky AG. Wilkinson S, et al. Among authors: abdul sater h. Eur Urol. 2021 Dec;80(6):746-757. doi: 10.1016/j.eururo.2021.03.009. Epub 2021 Mar 27. Eur Urol. 2021. PMID: 33785256 Free PMC article.
15 results